Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kailera
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For participants without diabetes mellitus at screening and on Day 1, BMI ≥30 kilograms/square meter (kg/m\^2) or BMI ≥27 kg/m\^2 and a previous diagnosis of at least 1 of the following:
* Hypertension
* Dyslipidemia
* Obstructive sleep apnea
* Cardiovascular disease
For participants living with type 2 diabetes mellitus and BMI ≥27 kg/m\^2 only:
* Diagnosis of type 2 diabetes mellitus
* On stable therapy for type 2 diabetes mellitus for at least 3 months prior to screening
You may not be if
For participants without diabetes:
* Laboratory evidence of diabetes
* Taking a concomitant medication for the indication of glycemic control
For participants living with type 2 diabetes mellitus only:
* History of diabetic ketoacidosis or hyperosmolar state/coma within 1 year of screening
* History of severe hypoglycemia or hypoglycemia unawareness within 1 year of screening
* History of proliferative diabetic retinopathy, diabetic maculopathy, or nonproliferative diabetic retinopathy that required acute treatment
Started medications that may cause significant weight change within 3 months prior to screening, including tricyclic antidepressants, atypical antipsychotics, and mood stabilizers
Unstable weight defined as self-reported change in body weight exceeding 5% within 3 months prior to screening
Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid carcinoma
Uncontrolled hypertension or unstable cardiovascular disease
History of chronic or acute pancreatitis
Known clinically significant gastric-emptying abnormality or chronic treatment with medications that directly affect gastrointestinal motility
History of suicide attempt
History of significant active or unstable major depressive disorder or other severe psychiatric disorder
Received treatment with semaglutide, tirzepatide, glucagon-like peptide-1 (GLP-1) receptor agonist, GLP-1/glucose-dependent insulinotropic polypeptide receptor agonist, or glucagon receptor agonist within the last 3 months prior to screening
Clareo Health | Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
